Blog
A new take on developing drugs for chronic pain
Despite a recent failure, Lilly’s master protocol trial shows a path forward in chronic pain R&D.
Red flags in biotech press releases
Learn the classic signs of spin and misdirection in biotech PR about clinical trial results.
How risky is that biotech trial?
A framework to more methodically assess clinical development probability of success (POS).
Introductory resources for analyzing biotech clinical trial results (updated 3/28/24)
Learn to analyze biotech trials like a pro!